Pasar al contenido principal

USO DE LA TECNOLOGIA CRISPR/CAS9 PARA LA IDENTIFICACION DE NUEVOS MARCADORES METASTASICOS EN CANCER DE PROSTATA

PID2020-117650RA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

New and Old Key Players in Liver Cancer

  • Cuesta Martínez, Ángel
  • Palao, Nerea
  • Bragado Domingo, Paloma
  • Gutiérrez Uzquiza, Álvaro
  • Herrera González, Blanca María
  • Sánchez Muñoz, Aranzazu
  • Porras Gallo, María Almudena
Liver cancer represents a major health problem worldwide with growing incidence and high mortality, hepatocellular carcinoma (HCC) being the most frequent. Hepatocytes are likely the cellular origin of most HCCs through the accumulation of genetic alterations, although hepatic progenitor cells (HPCs) might also be candidates in specific cases, as discussed here. HCC usually develops in a context of chronic inflammation, fibrosis, and cirrhosis, although the role of fibrosis is controversial. The interplay between hepatocytes, immune cells and hepatic stellate cells is a key issue. This review summarizes critical aspects of the liver tumor microenvironment paying special attention to platelets as new key players, which exert both pro- and anti-tumor effects, determined by specific contexts and a tight regulation of platelet signaling. Additionally, the relevance of specific signaling pathways, mainly HGF/MET, EGFR and TGF-β is discussed. HGF and TGF-β are produced by different liver cells and platelets and regulate not only tumor cell fate but also HPCs, inflammation and fibrosis, these being key players in these processes. The role of C3G/RAPGEF1, required for the proper function of HGF/MET signaling in HCC and HPCs, is highlighted, due to its ability to promote HCC growth and, regulate HPC fate and platelet-mediated actions on liver cancer.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C3G down-regulation enhances pro-migratory and stemness properties of oval cells by promoting an epithelial-mesenchymal-like process

  • Palao, Nerea
  • Sequera, Celia
  • Cuesta, Ángel M.
  • Baquero, Cristina
  • Bragado, Paloma
  • Gutiérrez-Uzquiza, Álvaro
  • Sánchez, Aranzazu
  • Guerrero Arroyo, María del Carmen
  • Porras, Almudena
Previous data indicate that C3G (RapGEF1) main isoform is highly expressed in liver progenitor cells (or oval cells) compared to adult mature hepatocytes, suggesting it may play an important role in oval cell biology. Hence, we have explored C3G function in the regulation of oval cell properties by permanent gene silencing using shRNAs. We found that C3G knock-down enhanced migratory and invasive ability of oval cells by promoting a partial epithelial to mesenchymal transition (EMT). This is likely mediated by upregulation of mRNA expression of the EMT-inducing transcription factors, Snail1, Zeb1 and Zeb2, induced in C3G-silenced oval cells. This EMT is associated to a higher expression of the stemness markers, CD133 and CD44. Moreover, C3G down-regulation increased oval cells clonogenic capacity by enhancing cell scattering. However, C3G knock-down did not impair oval cell differentiation into hepatocyte lineage. Mechanistic studies revealed that HGF/MET signaling and its pro-invasive activity was impaired in oval cells with low levels of C3G, while TGF-β signaling was increased. Altogether, these data suggest that C3G might be tightly regulated to ensure liver repair in chronic liver diseases such as non-alcoholic steatohepatitis. Hence, reduced C3G levels could facilitate oval cell expansion, after the proliferation peak, by enhancing migration., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness [SAF2013-48210-C2-2-R, SAF2016-76588-C2-1-R and PID2019-104143RB-C22 to AP funded by MCIN/ AEI/ 10.13039/501100011033; SAF2013-48210-C2-1-R, SAF2016-76588-C2-2-R and PID2019-104143RB-C21 to CG; PID2019-104991RB-I00 to PB, PID2020-117650RA-I00 to A G-U and RTI2018-099098-B-100 to AS], and by two grants from the Council of Education of Junta de Castilla y León, Spain [SA157A12-1 and SA017U16 to CG]. All funding was cosponsored by the European FEDER Program. NP is a recipient of FPU fellowship from Spanish Ministry of Education. CS was supported by a fellowship from Complutense University from Madrid and CB by PID2019-104143RB-C22 contract and “Program for young employment from Madrid Community (PEJD-2019-PRE_BMD-14083). A G-U is supported by Madrid Community Program for Talent Attraction (MRF 2017-T1/BMD-5468).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis

  • Rodrigo-Faus, María
  • Vincelle-Nieto, África
  • Vidal, Natalia
  • Puente, Javier
  • Saiz-Pardo, Melchor
  • López-García, Alejandra
  • Mendiburu-Eliçabe, Marina
  • Palao, Nerea
  • Baquero, Cristina
  • Linzoain-Agos, Paula
  • Cuesta, Ángel M.
  • Qu, Hui-Qi
  • Hakonarson,Hakon
  • Musteanu, Mónica
  • Reyes-Palomares, Armando
  • Porras, Almudena
  • Bragado, Paloma
  • Gutiérrez-Uzquiza, Álvaro
Due to the limited effectiveness of current treatments, the survival rate of patients with metastatic castration-resistant prostate cancer (mCRPC) is significantly reduced. Consequently, it is imperative to identify novel therapeutic targets for managing these patients. Since the invasive ability of cells is crucial for establishing and maintaining metastasis, the aim of this study was to identify the essential regulators of invasive abilities of mCRPC cells by conducting two independent high-throughput CRISPR/Cas9 screenings. Furthermore, some of the top hits were validated using siRNA technology, with protein arginine methyltransferase 7 (PRMT7) emerging as the most promising candidate. We demonstrated that its inhibition or depletion via genetic or pharmacological approaches significantly reduces invasive, migratory and proliferative abilities of mCRPC cells in vitro. Moreover, we confirmed that PRMT7 ablation reduces cell dissemination in chicken chorioallantoic membrane and mouse xenograft assays. Molecularly, PRMT7 reprograms the expression of several adhesion molecules by methylating various transcription factors, such as FoxK1, resulting in the loss of adhesion from the primary tumor and increased motility of mCRPC cells. Furthermore, PRMT7 higher expression correlates with tumor aggressivity and poor overall survival in prostate cancer patients. Thus, this study demonstrates that PRMT7 is a potential therapeutic target and potential biomarker for mPCa., This work was funded by Comunidad de Madrid under projects 2017-T1/BMD-5468 and 2021-5A/BMD-20956; Grants (PID2020-117650RA-I00 (AGU), PID2019-104143RB-C22 (AP), PID2019-104991RB-I00 (PB) and PID2021-122797OB-I00 (MM)) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; and ARP and AVN have been supported and granted by the Regional Programme of Research and Technological Innovation for Young Doctors UCM-CAM (PR65/19–22460)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Platelet C3G protects from liver fibrosis, while enhancing tumor growth through regulation of the immune response

  • Baquero, Cristina
  • Iniesta-González, Minerva
  • Palao, Nerea
  • Fernández-Infante, Cristina
  • Cueto-Remacha, Mateo
  • Mancebo, Jaime
  • Cámara-Fuentes, Samuel de la
  • Rodrigo-Faus, María
  • Valdecantos, M. P.
  • Valverde, Ángela M.
  • Sequera, Celia
  • Manzano, Sara
  • Cuesta, Ángel M.
  • Gutiérrez-Uzquiza, Álvaro
  • Bragado, Paloma
  • Guerrero, Carmen
  • Porras, Almudena
Primary liver cancer usually occurs in the context of chronic liver disease (CLD), in association with fibrosis. Platelets have emerged as important regulators of CLD and liver cancer, although their precise function and mechanism of action need to be clarified. C3G (RapGEF1) regulates platelet activation, adhesion, and secretion. Here we evaluate the role of platelet C3G in chemically induced fibrosis and liver cancer associated with fibrosis using genetically modified mouse models. We found that while overexpression of full-length C3G in platelets decreased liver fibrosis induced by chronic treatment with CCl4, overexpressed C3G lacking the catalytic domain did not, although in both cases platelet recruitment to the liver was similar. In addition, C3G deletion in platelets (PF4-C3GKO mouse model) increased CCl4-induced liver damage and hepatic fibrosis, reducing liver platelets and macrophages. Moreover, early liver immune response to CCl4 was altered in PF4-C3GKO mice, with a remarkable lower activation of macrophages and increased monocyte-derived macrophages compared to WT mice. On the other hand, in response to DEN+CCl4, PF4-C3G WT mice exhibited more and larger liver tumors than PF4-C3GKO mice, accompanied by the presence of more platelets, despite having less fibrosis in previous steps. Liver immune cell populations were also differentially regulated in PF4-C3GKO mice, highlighting the higher number of macrophages, likely with a pro-inflammatory phenotype, present in the liver in response to chronic DEN+CCl4 treatment. Proteins upregulated or downregulated in platelet-rich plasma from PF4-C3GKO compared to WT mice might regulate the immune response and tumor development. In this regard, enrichment analyses using proteomic data showed changes in several proteins involved in platelet activation and immune response pathways. Additionally, the higher secretion of CD40L by PF4-C3GKO platelets could contribute to their antitumor effect. Therefore, platelet C3G presents antifibrotic and protumor effects in the liver, likely mediated by changes in the immune response. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness and Science, Innovation and Universities (PID2022-137717OB-C21 to AP/AMC; PID2019-104143RB-C22 to AP; PID2022-137717OB-C22 to CG; PID2019-104143RB-C21 to CG; PID2019-104991RB-I00 and PID2022-136959OB-I00 to PB, PID2020-117650RA-I00 and CNS2023-144109 to AG-U, PID-2021-122766OB-100 to AVM and funded by MICIU/AEI/10.13039/501100011033). All funding was cosponsored by the European ‘ERDF A way of making Europe’. CB was supported by Grant PID2019-104143RB-C22. NP was a recipient of a Formacion de Profesorado Universitario fellowship from the Spanish Ministry of Education. MI is supported by a predoctoral contract from Comunidad de Madrid. MC is a recipient of a predoctoral contract from UCM., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deletion of C3G in hepatocytes impairs full liver maturation and alters glucose homeostasis

  • Palao, Nerea
  • Mancebo, Jaime
  • Baquero, Cristina
  • Iniesta-González, Minerva
  • Cueto-Remacha, Mateo
  • Rodrigo-Faus, María
  • Gutiérrez-Uzquiza, Álvaro
  • Bragado, Paloma
  • Cuesta, Ángel M.
  • Sánchez, Aranzazu
  • Guerrero Arroyo, María del Carmen
  • Porras, Almudena
C3G (RapGEF1) regulates the biology of liver hepatic progenitor cells and hepatocarcinoma cells, but its role in hepatocytes remained unknown. Therefore, we generated a mouse model lacking C3G in hepatocytes (C3GKOAlb), which showed liver damage as evidenced by increased fibrosis, liver macrophages and serum transaminases activity. Furthermore, impaired liver maturation was observed in C3GKOAlb mice demonstrated by the low expression of hepatocyte specific proteins (i.e. HNF4α), but higher levels of Alpha-fetoprotein, and stemness markers (i.e. CD133). Glucose homeostasis was also altered in C3GKOAlb mice, as well as insulin and glucagon effects on hepatocytes, which resulted in reduced serum glucose levels and an enhanced response to glucagon. In addition, the expression of several glycolytic and gluconeogenic enzymes, as well as the levels of the active form of Glycogen phosphorylase (PYGL), were upregulated in livers from C3GKOAlb mice, being remarkable the increased Pyruvate kinase isoform 2 (PKM2) levels accompanied by higher serum lactate concentrations. An increased expression of the ketogenic enzyme 3-hydroxy 3-methylglutaryl-CoA (HMG) synthase (Hmgcs2) was also found in these livers in parallel to elevated blood levels of beta-hydroxy-butyrate. Moreover, the fasting response was enhanced in C3GKOAlb mice as compared to wt animals. Hence, livers lacking C3G in hepatocytes showed a higher expression of gluconeogenic, lipogenic and ketogenic enzymes than livers from wt mice and enhanced ketogenesis. Mechanistically, data support a PTBP1-mediated upregulation of PKM2 expression in hepatocytes lacking C3G, which leads to enhanced glycolysis. Other metabolic alterations are likely due to the defective insulin signaling and the enhanced glucagon signaling through a cAMP-PKA-dependent mechanism. In summary, we have identified a novel role for C3G in the liver as a key mediator of hepatocyte differentiation and metabolic functions of hepatocytes. Hence, its absence leads to an immature phenotype and an altered response to insulin and glucagon, favoring glucagon actions., This work was supported by grants from the Spanish Ministry of Science, Innovation and Universities [PID2022-137717OB-C21 to AP/AMC; PID2019-104143RB-C22 to AP; PID2022-137717OB-C22 to CG; PID2019-104143RB-C21 to CG; PID2021-124830OB-I00 to AS; PID2019-104991RB-I00 and PID2022-136959OB-I00 to PB, PID2020-117650RA-I00 and CNS2023-144109 to AG-U, PID2021-124830OB-I00 to AS and funded by MICIU/AEI/10.13039/501100011033]. All funding was cosponsored by the European “ERDF A way of making Europe”. NP was a recipient of an FPU fellowship from the Spanish Ministry of Education. CB was supported by the PID2019-104143RB-C22 grant. MI-G is supported by a predoctoral contract from Comunidad de Madrid. MC-R is a recipient of a predoctoral contract from UCM and JM by the PID2022-137717OB-C21 grant., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

New and Old Key Players in Liver Cancer

  • Cuesta Martínez, Ángel
  • Palao, Nerea
  • Bragado Domingo, Paloma
  • Gutiérrez Uzquiza, Álvaro
  • Herrera González, Blanca María
  • Sánchez Muñoz, Aranzazu
  • Porras Gallo, María Almudena
Liver cancer represents a major health problem worldwide with growing incidence and high mortality, hepatocellular carcinoma (HCC) being the most frequent. Hepatocytes are likely the cellular origin of most HCCs through the accumulation of genetic alterations, although hepatic progenitor cells (HPCs) might also be candidates in specific cases, as discussed here. HCC usually develops in a context of chronic inflammation, fibrosis, and cirrhosis, although the role of fibrosis is controversial. The interplay between hepatocytes, immune cells and hepatic stellate cells is a key issue. This review summarizes critical aspects of the liver tumor microenvironment paying special attention to platelets as new key players, which exert both pro- and anti-tumor effects, determined by specific contexts and a tight regulation of platelet signaling. Additionally, the relevance of specific signaling pathways, mainly HGF/MET, EGFR and TGF-β is discussed. HGF and TGF-β are produced by different liver cells and platelets and regulate not only tumor cell fate but also HPCs, inflammation and fibrosis, these being key players in these processes. The role of C3G/RAPGEF1, required for the proper function of HGF/MET signaling in HCC and HPCs, is highlighted, due to its ability to promote HCC growth and, regulate HPC fate and platelet-mediated actions on liver cancer.